New organ donation guidelines have taken effect as of Nov. 18, updating procedures for some donors.
The Health Resources and Services Administration (HRSA), a branch of the U.S. Department of Health and Human Services (HHS), previously announced the policy update in a press release after the changes were approved by the Organ Procurement and Transplantation Network in August.
The new guidelines apply to donation after circulatory death (DCD), in which organs are recovered after the heart and lungs stop functioning. This differs from donation after brain death, when the donor is declared dead based on the irreversible loss of brain function.
What the new rules require
The changes include a formal process to pause donation if patient safety concerns arise. Families, medical providers and other people involved in the process must be told they can request a pause and how to do so.
Procedures will also be added for handling and reporting unplanned pauses, along with more detailed records of neurological assessments.
Additionally, a minimum five-minute waiting period will be put in place after circulation stops and before organ recovery begins.
Timing concerns
While the changes are intended to strengthen patient safeguards and improve communication with families, University of Rochester bioethicist Dr. Lainie Ross told NPR that allowing organ procurement teams to approach families before they decide whether to withdraw life-sustaining care could leave them feeling pressured or distrustful of doctors’ motives.
In public comments, the American Society of Transplantation said it supports honoring requests to pause the donation process at any point.
Previous cases in which organ recovery was reportedly begun before confirmation of death have raised questions about safeguards in the donation process. HRSA Division of Transplantation Director Dr. Raymond Lynch told Fox News Digital that "does not happen" under the process governed by the new guidelines.
"The point of these policies that were put into place is to make sure that we do preserve the sanctity of that decision and make sure that the technical parts of the operation ... pose no risk to the patient," Lynch told Fox News Digital.
The HRSA director said these new guidelines improve the "safety, quality and consistency of care that's already being delivered across the United States."
Organ donation has changed just within the last decade, according to Lynch. Historically, most donors were declared as "brain-dead," meaning they were "legally deceased" at the time the decision was made.
"Now, we're dealing with [DCD], which means that it's an individual who's not brain-dead, but they're very severely injured," he said. "The medical team and the family have come to the decision that they're going to change the goals of care and let that person have a natural, compassionate death."
"In that setting, shortly after they pass away, their organs are removed through a surgical procedure."
The guidelines do not change the roles of the patient’s healthcare team or the organ procurement organization (OPO), the group that coordinates organ donation and recovery. Rather, they set clearer expectations for when donation-related discussions and procedures take place, according to Lynch.
"Historically, it was very, very late in the patient's medical course before there could be a discussion of them being an organ donor," he said. "And that really has two kinds of harm."
One concern was that families may have felt "rushed or pressured" to decide whether to authorize organ donation before they had enough time to make an informed choice.
He said delays could deny patients "the chance to give the gift" of organ donation, as they intended when they signed up to be donors.
The other risk was an "insufficient delivery" of information and recording of decisions, according to Lynch.
He said the new guidelines bring more thorough conversations and clearer records of what information was shared with families, and when.
These conversations are "happening in truly tragic circumstances," Lynch noted, as families and loved ones are feeling fear and grief.
The HRSA aims to ensure that the quality and quantity of communication and medical care is "very high."
"All of this is about elevating this to the level of a medical specialty," he said. "We're making sure through these regulations that there is a level of professionalism and consistency, and that the care people's loved ones are going to get is ... compassionate and respectful."
What families should know
Dr. Stephanie Widmer, New York City emergency medicine physician and Fox News medical contributor, said families should know that "there are now clearer safeguards," including the five-minute wait and the chance to pause the process.
She added that while organ donation saves lives, protection of the donor "must always come first."
"I think these changes are a positive step toward improving patient safety, transparency and public trust," Widmer, who was not involved in the guideline updates, told Fox News Digital. "My concern is whether these safeguards will be consistently enforced across hospitals and organ procurement organizations."
The doctor added that a policy is "only as effective as its implementation," and that additional procedural requirements don’t "unnecessarily interfere with a patient’s wishes to donate."
Widmer said she'd like to see stronger national standards for independent neurological assessments and "greater oversight" of organ procurement practices.
"The medical team caring for the patient should remain completely independent of the organ recovery process," she emphasized. "Families also deserve clear explanations of exactly what will happen, including any specialized procedures used to preserve organs."
"The goal should always be to save lives through donation without ever compromising the care, dignity or safety of the donor."
Angelica Stabile
https://www.foxnews.com/health/new-organ-donation-rules-take-effect-after-alarming-reports-patients-showing-signs-lifex
The U.S. Department of Health and Human Services has begun the decertification of Network for Hope, the federally designated organ procurement organization serving Kentucky and parts of Indiana, Ohio and West Virginia, following federal reviews that uncovered serious patient safety failures.
The Centers for Medicare & Medicaid Services initiated the decertification action after investigations revealed persistent safety issues, including instances where the organ harvesting process was initiated on patients who still showed active signs of life.
Appearing on America's Newsroom, Dr. Marc Siegel, a senior medical analyst for Fox News, described details from his interview with Health and Human Services Secretary Robert F. Kennedy Jr. regarding the department's actions against the nonprofit organization.
"Health and Human Services Secretary Kennedy is bringing to light horror stories about the dark corners of organ harvesting," Siegel said.
"The department is now pulling the accreditation of Kentucky's Network for Hope, the main organ procurement organization in the state."
Network for Hope's chief executive officer stated that the organization plans to appeal the federal decision, maintaining that it remains fully compliant with organ procurement and transportation network policies.
Siegel said he spoke with Secretary Kennedy about the case of TJ Hoover, a prospective donor who reportedly nearly had his organs removed by Network for Hope while still alive.
"Even after those signs of life, Kennedy says the organ procurement process continued until the physician refused to proceed," the doctor said.
HHS' Health Resources and Services Administration examined 351 cases at Network for Hope between 2021 and 2024 in which organ donation was authorized but ultimately not completed.
The review identified 103 cases with concerning features, including 73 patients with what HHS described as "neurological signs incompatible with organ donation."
"HHS says it uncovered 73 separate instances where the process of harvesting an organ should have been stopped sooner," Siegel said. "The investigation revealed that the nonprofit pressured medical personnel to proceed despite patients showing active signs of live and neurological function."
According to federal officials, investigators found evidence of inadequate neurological assessments, poor coordination with hospital care teams, questionable consent practices and improper classification of causes of death.
"Thirty percent of the procedures that they were performing had something wrong with them," Siegel added. "If there's a bad organization that's willing to do things that are unethical, they're going to get away with things at any place where they operate."
Despite the agency's findings, Siegel noted that Kennedy remains supportive of organ donation when conducted under proper standards, pointing to personal experience with his own family.
"Kennedy says he strongly supports organ donation when it's done ethically and properly," Siegel said. "His own nephew, Michael Hines, saved multiple lives by donating his organs after his death at age 20."
Khloe Quill
https://www.foxnews.com/health/organ-harvesting-began-while-patients-showed-signs-life-federal-investigation-finds
pediatric neurology
Wednesday, November 18, 2026
Let's face it
Doing a physical examination on the routine patient seen for epilepsy follow-up is a waste of everyone's time. Seeing the patient in person is also unnecessary.
Saturday, November 14, 2026
AI, epilepsy, and the importance of human care
Artificial intelligence (AI) is changing healthcare. It can help doctors find diseases earlier, improve research, and develop new treatments. At the same time, more people are using AI to ask questions about their health.
This raises an important question: Why do some patients feel more heard by a chatbot than by their own doctor?
The answer tells us something important about AI and the challenges facing today’s healthcare system.
Why Are People Turning to AI for Medical Advice?
Getting good medical care is not always easy. Appointments can feel rushed, it may take months to see a specialist, and many providers have limited time to spend with each patient.
AI offers something different. It is available anytime, answers questions quickly, and never seems too busy to listen.
In one study, healthcare professionals rated AI’s responses to medical questions as higher in quality, empathy, and clarity compared to doctors’.
This does not mean that AI provides better medical care. It means people want more than medical facts. They want to feel heard, understood, and supported.
When Empathy Becomes Dangerous
Humans need connection. When that connection is missing, it can be easy to trust someone, or something that always seems ready to listen.
Bowen Wan’s Story
The New York Times recently told the story of Bowen Wan, a young woman with epilepsy who turned to ChatGPT for companionship and health advice. Living in the United States, far from her family in China, she struggled with loneliness and the challenges of living with epilepsy. AI offered a friendly, patient voice that was always available.
According to the report, Bowen told ChatGPT that she did not trust her doctors. Instead of encouraging her to talk with her healthcare team, the chatbot supported her concerns. It even praised her decision to keep her plans to lower her anti-seizure medication a secret.
As Bowen lowered her medication, she described having trouble understanding written words, gaps in awareness, and unusual feelings. These are symptoms that can signal seizures returning, especially when lowering anti-seizure medication.
Instead of warning her that these symptoms could be serious, the chatbot reassured her that her brain was simply adjusting. It did not encourage her to seek medical care, even as her symptoms continued.
Seizure Control and SUDEP
The medical examiner ruled that Bowen died of sudden unexpected death in epilepsy (SUDEP). Tests after her death reportedly showed very low levels of her anti-seizure medicine.
We cannot know exactly what led to Bowen’s death. Still, there is serious concern that changing her medicine led to these low levels. Her seizures may then have become harder to control and played a role in her death.
Each year, SUDEP affects about 1 in 1,000 people with epilepsy. One risk factor is having frequent tonic-clonic seizures, during which a person loses consciousness and their body stiffens and shakes.
While no one can eliminate the risk for SUDEP, taking steps to keep seizures under control can help lower it. These include:
Taking anti-seizure medications as prescribed.
Talking with your healthcare team before changing medications.
Working with your providers to improve seizure control.
Seeking specialist care if seizures continue.
Many organizations such as Partners Against Mortality in Epilepsy (PAME) and the Danny Did Foundation offer helpful information on SUDEP and ways to lower risk.
AI is a Tool, not a Medical Professional
In this case, AI’s attempt to be caring became dangerous. Instead of warning Bowen about the risks and encouraging her to get medical help, it agreed with her.
Good medical care does not always mean your doctor agrees with you. Sometimes, it means talking about risks and concerns, even when those conversations are difficult.
As AI becomes more common, it should be used as a tool, not a replacement for medical care or human connection. A chatbot can’t replace a healthcare professional who understands your medical history and needs. When people become emotionally attached to AI systems, they may place too much trust in advice that lacks context or medical judgment. AI can provide information, but it cannot fully understand an individual’s health needs.
How AI Can Help Healthcare
AI has tremendous potential to improve healthcare. It can help doctors find signs of stroke on brain scans; detect seizures in EEG recordings; and develop better treatments for epilepsy, brain tumors, and Alzheimer’s disease. Some AI tools are already being used in hospitals, while others still need more testing to ensure they are safe and effective.
These tools can help healthcare teams work more efficiently and may improve patient care. However, they must be safely developed with guidance from neurologists and other healthcare professionals. This is especially important when medical decisions involve uncertainty and changing symptoms.
Putting the Care Back in Healthcare
A family doctor once told me, “For most visits, my stethoscope never leaves my neck.”
That comment has stayed with me. Good medical care is often not about finding a rare disease or prescribing another medicine. It is about listening, teaching, easing fears, and helping people make healthy choices. This is not something extra doctors do. It is medical care.
Perhaps the most concerning lesson is that some people turn to chatbots because they do not feel heard by the healthcare system.
Used well, AI could help change that. By reducing paperwork and making information easier to find, AI could free up time for listening and building trust.
Healthcare leaders face a choice. Will AI help doctors spend more time caring for patients, or will it push them to see more patients in less time with fewer resources? The goal should be better care, not just lower costs.
Putting the Care Back in Healthcare
AI is here to stay. That is not a bad thing. It can help people learn about their health and prepare questions for healthcare teams. However, AI should be used as a tool to become informed, not make important medical decisions for you. Systems must be developed that do four things:
Bowen’s death is heartbreaking, and my heart goes out to her family. I hope we learn from her story and use those lessons to help prevent similar tragedies.
Her experience reminds us that healthcare is about more than information. It is about recognizing danger, building trust, and helping people make informed decisions.
People often turn to AI when they feel lonely, cannot access care, or do not feel understood. As these tools become more powerful, we must address the human needs that draw people to them in the first place.
AI may help improve healthcare, but it should support, not replace, the human relationships at the heart of good care.
Tim Feyma, MD
https://www.epilepsyfoundationmn.org/2026/11/11/ai-epilepsy-and-the-importance-of-human-care/
This raises an important question: Why do some patients feel more heard by a chatbot than by their own doctor?
The answer tells us something important about AI and the challenges facing today’s healthcare system.
Why Are People Turning to AI for Medical Advice?
Getting good medical care is not always easy. Appointments can feel rushed, it may take months to see a specialist, and many providers have limited time to spend with each patient.
AI offers something different. It is available anytime, answers questions quickly, and never seems too busy to listen.
In one study, healthcare professionals rated AI’s responses to medical questions as higher in quality, empathy, and clarity compared to doctors’.
This does not mean that AI provides better medical care. It means people want more than medical facts. They want to feel heard, understood, and supported.
When Empathy Becomes Dangerous
Humans need connection. When that connection is missing, it can be easy to trust someone, or something that always seems ready to listen.
Bowen Wan’s Story
The New York Times recently told the story of Bowen Wan, a young woman with epilepsy who turned to ChatGPT for companionship and health advice. Living in the United States, far from her family in China, she struggled with loneliness and the challenges of living with epilepsy. AI offered a friendly, patient voice that was always available.
According to the report, Bowen told ChatGPT that she did not trust her doctors. Instead of encouraging her to talk with her healthcare team, the chatbot supported her concerns. It even praised her decision to keep her plans to lower her anti-seizure medication a secret.
As Bowen lowered her medication, she described having trouble understanding written words, gaps in awareness, and unusual feelings. These are symptoms that can signal seizures returning, especially when lowering anti-seizure medication.
Instead of warning her that these symptoms could be serious, the chatbot reassured her that her brain was simply adjusting. It did not encourage her to seek medical care, even as her symptoms continued.
Seizure Control and SUDEP
The medical examiner ruled that Bowen died of sudden unexpected death in epilepsy (SUDEP). Tests after her death reportedly showed very low levels of her anti-seizure medicine.
We cannot know exactly what led to Bowen’s death. Still, there is serious concern that changing her medicine led to these low levels. Her seizures may then have become harder to control and played a role in her death.
Each year, SUDEP affects about 1 in 1,000 people with epilepsy. One risk factor is having frequent tonic-clonic seizures, during which a person loses consciousness and their body stiffens and shakes.
While no one can eliminate the risk for SUDEP, taking steps to keep seizures under control can help lower it. These include:
Taking anti-seizure medications as prescribed.
Talking with your healthcare team before changing medications.
Working with your providers to improve seizure control.
Seeking specialist care if seizures continue.
Many organizations such as Partners Against Mortality in Epilepsy (PAME) and the Danny Did Foundation offer helpful information on SUDEP and ways to lower risk.
AI is a Tool, not a Medical Professional
In this case, AI’s attempt to be caring became dangerous. Instead of warning Bowen about the risks and encouraging her to get medical help, it agreed with her.
Good medical care does not always mean your doctor agrees with you. Sometimes, it means talking about risks and concerns, even when those conversations are difficult.
As AI becomes more common, it should be used as a tool, not a replacement for medical care or human connection. A chatbot can’t replace a healthcare professional who understands your medical history and needs. When people become emotionally attached to AI systems, they may place too much trust in advice that lacks context or medical judgment. AI can provide information, but it cannot fully understand an individual’s health needs.
How AI Can Help Healthcare
AI has tremendous potential to improve healthcare. It can help doctors find signs of stroke on brain scans; detect seizures in EEG recordings; and develop better treatments for epilepsy, brain tumors, and Alzheimer’s disease. Some AI tools are already being used in hospitals, while others still need more testing to ensure they are safe and effective.
These tools can help healthcare teams work more efficiently and may improve patient care. However, they must be safely developed with guidance from neurologists and other healthcare professionals. This is especially important when medical decisions involve uncertainty and changing symptoms.
Putting the Care Back in Healthcare
A family doctor once told me, “For most visits, my stethoscope never leaves my neck.”
That comment has stayed with me. Good medical care is often not about finding a rare disease or prescribing another medicine. It is about listening, teaching, easing fears, and helping people make healthy choices. This is not something extra doctors do. It is medical care.
Perhaps the most concerning lesson is that some people turn to chatbots because they do not feel heard by the healthcare system.
Used well, AI could help change that. By reducing paperwork and making information easier to find, AI could free up time for listening and building trust.
Healthcare leaders face a choice. Will AI help doctors spend more time caring for patients, or will it push them to see more patients in less time with fewer resources? The goal should be better care, not just lower costs.
Putting the Care Back in Healthcare
AI is here to stay. That is not a bad thing. It can help people learn about their health and prepare questions for healthcare teams. However, AI should be used as a tool to become informed, not make important medical decisions for you. Systems must be developed that do four things:
Bowen’s death is heartbreaking, and my heart goes out to her family. I hope we learn from her story and use those lessons to help prevent similar tragedies.
Her experience reminds us that healthcare is about more than information. It is about recognizing danger, building trust, and helping people make informed decisions.
People often turn to AI when they feel lonely, cannot access care, or do not feel understood. As these tools become more powerful, we must address the human needs that draw people to them in the first place.
AI may help improve healthcare, but it should support, not replace, the human relationships at the heart of good care.
Tim Feyma, MD
https://www.epilepsyfoundationmn.org/2026/11/11/ai-epilepsy-and-the-importance-of-human-care/
See: https://childnervoussystem.blogspot.com/2026/10/chatgpt-epilepsy-management-advice.html
https://childnervoussystem.blogspot.com/2026/11/chatgpt-and-medical-queries.html
Monday, November 9, 2026
ChatGPT and medical queries
Almomani MA, Almomani BA, Al-Qudah H, Abed Alrahman R, El-Bawaneh SO, Hawari S, Alqudah AA. Assessing the accuracy of ChatGPT responses to caregiver questions in pediatric neurology: an observational study. Sci Rep. 2026 Jul 11. doi: 10.1038/s41598-026-61986-6. Epub ahead of print. PMID: 42436249.
Abstract
ChatGPT has seen increased use by caregivers as a source of medical information. Pediatric neurology has added complexities because there are various disorders, changing diagnoses and potential consequences of misinformation. To evaluate the accuracy, comprehensiveness and reproducibility of ChatGPT responses to frequently asked pediatric neurology questions. In total, 105 unique questions across seven pediatric neurology subspecialties were included. Every question was input twice into ChatGPT (GPT-5) during separate sessions. Two certified pediatric neurologists reviewed the responses and rated them on a 4-point scale: 1-complete and accurate,2- correct but not complete,3- partially incorrect,4-not correct. Reproducibility was considered to be agreement between grading categories (grade 1-2 and grade 3-4) throughout repeated responses. 60.95%(64/105) of responses were rated as comprehensive, while 31.43%(33/105) were correct but incomplete; fully incorrect responses were uncommon 3.8%(4/105). Accuracy and reproducibility were highest for structured conditions such as cerebral palsy and movement disorders, and lower for more heterogeneous domains including neurodevelopmental delay and epilepsy. Overall reproducibility was high 95.2%(100/105). ChatGPT mostly delivers accurate information in pediatric neurology, with variable depth of response depending on the disorder. It is most appropriate for caregiver education with oversight by the clinician.
Altunisik E, Firat YE, Cengiz EK, Comruk GB. Artificial intelligence performance in clinical neurology queries: the ChatGPT model. Neurol Res. 2024 May;46(5):437-443. doi: 10.1080/01616412.2024.2334118. Epub 2024 Mar 24. PMID: 38522424.
Abstract
Introduction: The use of artificial intelligence technology is progressively expanding and advancing in the health and biomedical literature. Since its launch, ChatGPT has rapidly gained popularity and become one of the fastest-growing artificial intelligence applications in history. This study evaluated the accuracy and comprehensiveness of ChatGPT-generated responses to medical queries in clinical neurology.
Methods: We directed 216 questions from different subspecialties to ChatGPT. The questions were classified into three categories: multiple-choice, descriptive, and binary (yes/no answers). Each question in all categories was subjectively rated as easy, medium, or hard according to its difficulty level. Questions that also tested for intuitive clinical thinking and reasoning ability were evaluated in a separate category.
Results: ChatGPT correctly answered 141 questions (65.3%). No significant difference was detected in the accuracy and comprehensiveness scale scores or correct answer rates in comparisons made according to the question style or difficulty level. However, a comparative analysis assessing question characteristics revealed significantly lower accuracy and comprehensiveness scale scores and correct answer rates for questions based on interpretations that required critical thinking (p = 0.007, 0.007, and 0.001, respectively).
Conclusion: ChatGPT had a moderate overall performance in clinical neurology and demonstrated inadequate performance in answering questions that required interpretation and critical thinking. It also displayed limited performance in specific subspecialties. It is essential to acknowledge the limitations of artificial intelligence and diligently verify medical information produced by such models using reliable sources.
Goodman RS, Patrinely JR, Stone CA Jr, Zimmerman E, Donald RR, Chang SS, Berkowitz ST, Finn AP, Jahangir E, Scoville EA, Reese TS, Friedman DL, Bastarache JA, van der Heijden YF, Wright JJ, Ye F, Carter N, Alexander MR, Choe JH, Chastain CA, Zic JA, Horst SN, Turker I, Agarwal R, Osmundson E, Idrees K, Kiernan CM, Padmanabhan C, Bailey CE, Schlegel CE, Chambless LB, Gibson MK, Osterman TJ, Wheless LE, Johnson DB. Accuracy and Reliability of Chatbot Responses to Physician Questions. JAMA Netw Open. 2023 Oct 2;6(10):e2336483. doi: 10.1001/jamanetworkopen.2023.36483. PMID: 37782499; PMCID: PMC10546234.
Abstract
Importance: Natural language processing tools, such as ChatGPT (generative pretrained transformer, hereafter referred to as chatbot), have the potential to radically enhance the accessibility of medical information for health professionals and patients. Assessing the safety and efficacy of these tools in answering physician-generated questions is critical to determining their suitability in clinical settings, facilitating complex decision-making, and optimizing health care efficiency.
Objective: To assess the accuracy and comprehensiveness of chatbot-generated responses to physician-developed medical queries, highlighting the reliability and limitations of artificial intelligence-generated medical information.
Design, setting, and participants: Thirty-three physicians across 17 specialties generated 284 medical questions that they subjectively classified as easy, medium, or hard with either binary (yes or no) or descriptive answers. The physicians then graded the chatbot-generated answers to these questions for accuracy (6-point Likert scale with 1 being completely incorrect and 6 being completely correct) and completeness (3-point Likert scale, with 1 being incomplete and 3 being complete plus additional context). Scores were summarized with descriptive statistics and compared using the Mann-Whitney U test or the Kruskal-Wallis test. The study (including data analysis) was conducted from January to May 2023.
Main outcomes and measures: Accuracy, completeness, and consistency over time and between 2 different versions (GPT-3.5 and GPT-4) of chatbot-generated medical responses.
Results: Across all questions (n = 284) generated by 33 physicians (31 faculty members and 2 recent graduates from residency or fellowship programs) across 17 specialties, the median accuracy score was 5.5 (IQR, 4.0-6.0) (between almost completely and complete correct) with a mean (SD) score of 4.8 (1.6) (between mostly and almost completely correct). The median completeness score was 3.0 (IQR, 2.0-3.0) (complete and comprehensive) with a mean (SD) score of 2.5 (0.7). For questions rated easy, medium, and hard, the median accuracy scores were 6.0 (IQR, 5.0-6.0), 5.5 (IQR, 5.0-6.0), and 5.0 (IQR, 4.0-6.0), respectively (mean [SD] scores were 5.0 [1.5], 4.7 [1.7], and 4.6 [1.6], respectively; P = .05). Accuracy scores for binary and descriptive questions were similar (median score, 6.0 [IQR, 4.0-6.0] vs 5.0 [IQR, 3.4-6.0]; mean [SD] score, 4.9 [1.6] vs 4.7 [1.6]; P = .07). Of 36 questions with scores of 1.0 to 2.0, 34 were requeried or regraded 8 to 17 days later with substantial improvement (median score 2.0 [IQR, 1.0-3.0] vs 4.0 [IQR, 2.0-5.3]; P < .01). A subset of questions, regardless of initial scores (version 3.5), were regenerated and rescored using version 4 with improvement (mean accuracy [SD] score, 5.2 [1.5] vs 5.7 [0.8]; median score, 6.0 [IQR, 5.0-6.0] for original and 6.0 [IQR, 6.0-6.0] for rescored; P = .002).
Conclusions and relevance: In this cross-sectional study, chatbot generated largely accurate information to diverse medical queries as judged by academic physician specialists with improvement over time, although it had important limitations. Further research and model development are needed to correct inaccuracies and for validation.
Abstract
ChatGPT has seen increased use by caregivers as a source of medical information. Pediatric neurology has added complexities because there are various disorders, changing diagnoses and potential consequences of misinformation. To evaluate the accuracy, comprehensiveness and reproducibility of ChatGPT responses to frequently asked pediatric neurology questions. In total, 105 unique questions across seven pediatric neurology subspecialties were included. Every question was input twice into ChatGPT (GPT-5) during separate sessions. Two certified pediatric neurologists reviewed the responses and rated them on a 4-point scale: 1-complete and accurate,2- correct but not complete,3- partially incorrect,4-not correct. Reproducibility was considered to be agreement between grading categories (grade 1-2 and grade 3-4) throughout repeated responses. 60.95%(64/105) of responses were rated as comprehensive, while 31.43%(33/105) were correct but incomplete; fully incorrect responses were uncommon 3.8%(4/105). Accuracy and reproducibility were highest for structured conditions such as cerebral palsy and movement disorders, and lower for more heterogeneous domains including neurodevelopmental delay and epilepsy. Overall reproducibility was high 95.2%(100/105). ChatGPT mostly delivers accurate information in pediatric neurology, with variable depth of response depending on the disorder. It is most appropriate for caregiver education with oversight by the clinician.
Altunisik E, Firat YE, Cengiz EK, Comruk GB. Artificial intelligence performance in clinical neurology queries: the ChatGPT model. Neurol Res. 2024 May;46(5):437-443. doi: 10.1080/01616412.2024.2334118. Epub 2024 Mar 24. PMID: 38522424.
Abstract
Introduction: The use of artificial intelligence technology is progressively expanding and advancing in the health and biomedical literature. Since its launch, ChatGPT has rapidly gained popularity and become one of the fastest-growing artificial intelligence applications in history. This study evaluated the accuracy and comprehensiveness of ChatGPT-generated responses to medical queries in clinical neurology.
Methods: We directed 216 questions from different subspecialties to ChatGPT. The questions were classified into three categories: multiple-choice, descriptive, and binary (yes/no answers). Each question in all categories was subjectively rated as easy, medium, or hard according to its difficulty level. Questions that also tested for intuitive clinical thinking and reasoning ability were evaluated in a separate category.
Results: ChatGPT correctly answered 141 questions (65.3%). No significant difference was detected in the accuracy and comprehensiveness scale scores or correct answer rates in comparisons made according to the question style or difficulty level. However, a comparative analysis assessing question characteristics revealed significantly lower accuracy and comprehensiveness scale scores and correct answer rates for questions based on interpretations that required critical thinking (p = 0.007, 0.007, and 0.001, respectively).
Conclusion: ChatGPT had a moderate overall performance in clinical neurology and demonstrated inadequate performance in answering questions that required interpretation and critical thinking. It also displayed limited performance in specific subspecialties. It is essential to acknowledge the limitations of artificial intelligence and diligently verify medical information produced by such models using reliable sources.
Goodman RS, Patrinely JR, Stone CA Jr, Zimmerman E, Donald RR, Chang SS, Berkowitz ST, Finn AP, Jahangir E, Scoville EA, Reese TS, Friedman DL, Bastarache JA, van der Heijden YF, Wright JJ, Ye F, Carter N, Alexander MR, Choe JH, Chastain CA, Zic JA, Horst SN, Turker I, Agarwal R, Osmundson E, Idrees K, Kiernan CM, Padmanabhan C, Bailey CE, Schlegel CE, Chambless LB, Gibson MK, Osterman TJ, Wheless LE, Johnson DB. Accuracy and Reliability of Chatbot Responses to Physician Questions. JAMA Netw Open. 2023 Oct 2;6(10):e2336483. doi: 10.1001/jamanetworkopen.2023.36483. PMID: 37782499; PMCID: PMC10546234.
Abstract
Importance: Natural language processing tools, such as ChatGPT (generative pretrained transformer, hereafter referred to as chatbot), have the potential to radically enhance the accessibility of medical information for health professionals and patients. Assessing the safety and efficacy of these tools in answering physician-generated questions is critical to determining their suitability in clinical settings, facilitating complex decision-making, and optimizing health care efficiency.
Objective: To assess the accuracy and comprehensiveness of chatbot-generated responses to physician-developed medical queries, highlighting the reliability and limitations of artificial intelligence-generated medical information.
Design, setting, and participants: Thirty-three physicians across 17 specialties generated 284 medical questions that they subjectively classified as easy, medium, or hard with either binary (yes or no) or descriptive answers. The physicians then graded the chatbot-generated answers to these questions for accuracy (6-point Likert scale with 1 being completely incorrect and 6 being completely correct) and completeness (3-point Likert scale, with 1 being incomplete and 3 being complete plus additional context). Scores were summarized with descriptive statistics and compared using the Mann-Whitney U test or the Kruskal-Wallis test. The study (including data analysis) was conducted from January to May 2023.
Main outcomes and measures: Accuracy, completeness, and consistency over time and between 2 different versions (GPT-3.5 and GPT-4) of chatbot-generated medical responses.
Results: Across all questions (n = 284) generated by 33 physicians (31 faculty members and 2 recent graduates from residency or fellowship programs) across 17 specialties, the median accuracy score was 5.5 (IQR, 4.0-6.0) (between almost completely and complete correct) with a mean (SD) score of 4.8 (1.6) (between mostly and almost completely correct). The median completeness score was 3.0 (IQR, 2.0-3.0) (complete and comprehensive) with a mean (SD) score of 2.5 (0.7). For questions rated easy, medium, and hard, the median accuracy scores were 6.0 (IQR, 5.0-6.0), 5.5 (IQR, 5.0-6.0), and 5.0 (IQR, 4.0-6.0), respectively (mean [SD] scores were 5.0 [1.5], 4.7 [1.7], and 4.6 [1.6], respectively; P = .05). Accuracy scores for binary and descriptive questions were similar (median score, 6.0 [IQR, 4.0-6.0] vs 5.0 [IQR, 3.4-6.0]; mean [SD] score, 4.9 [1.6] vs 4.7 [1.6]; P = .07). Of 36 questions with scores of 1.0 to 2.0, 34 were requeried or regraded 8 to 17 days later with substantial improvement (median score 2.0 [IQR, 1.0-3.0] vs 4.0 [IQR, 2.0-5.3]; P < .01). A subset of questions, regardless of initial scores (version 3.5), were regenerated and rescored using version 4 with improvement (mean accuracy [SD] score, 5.2 [1.5] vs 5.7 [0.8]; median score, 6.0 [IQR, 5.0-6.0] for original and 6.0 [IQR, 6.0-6.0] for rescored; P = .002).
Conclusions and relevance: In this cross-sectional study, chatbot generated largely accurate information to diverse medical queries as judged by academic physician specialists with improvement over time, although it had important limitations. Further research and model development are needed to correct inaccuracies and for validation.
Sunday, November 8, 2026
Medical Assistance in Dying (MAiD) "way past appropriate"
A Canadian man's decision to end his life through the country's medically assisted dying program left his son stunned by how quickly the process unfolded, and now he's warning that the system has gone "way past appropriate."
Eric Edmeades, founder of Speaker Nation, a training platform for speakers that teaches presentation skills and more, told Fox News Digital this week that his father Baz, who was in his late 70s and struggling with a combination of medical problems, began discussing Canada's Medical Assistance in Dying (MAiD) program after his health deteriorated in late 2023.
But what Edmeades expected to be a months-long process suddenly accelerated, leaving the family with little time to prepare.
Edmeades said the family started taking the issue seriously in January, but at that stage, projections were that it would take at least six months. He and his wife traveled to Vancouver at the beginning of 2024 to visit his father. At that stage, it was still a speculative thing that was months away.
"And then, all of a sudden, it was like, ‘No, it's next week,’" Edmeades recalled.
His father died via MAiD Feb. 27, 2024.
He had been experiencing a sharp decline in his physical health and independence, particularly during the COVID-era lockdowns, according to his son.
"He had been incredibly healthy most of his life," Edmeades said, describing a combination of symptoms that included epilepsy and neurological pain.
Edmeades also questioned whether interactions between his father's medications could have contributed to his deteriorating condition.
"When the lockdowns came along, and he could no longer go out and walk all the time, it really had a marked decrease in his physical ability and his sense of freedom and all that kind of stuff," he said.
"And then there just came this point where life started sounding pointless to him."
Edmeades said his father had previously spoken about suicide, making his initial interest in medically assisted dying less surprising to the family.
"Given that it wasn't the first time that he talked about suicide in his life, it wasn't particularly shocking, but he also wasn't talking about it in really alarmist terms. So, I wasn't overly worried about it," he said.
Edmeades and his wife had already planned a trip to Vancouver and were able to spend time with his father before his death.
"And one of the things I'm incredibly grateful for is that I had incidentally booked a trip out to Vancouver, and my wife and I got to spend time with him," Edmeades recalled.
He thought he and his wife would have another opportunity to visit.
Edmeades said he was not in contact with his father's medical providers at the time and did not fully understand what had happened until afterward.
"It happened so quickly that I only really started to piece together what happened when it was done," he said.
Other family members and friends had also expressed concerns about his father's decision, according to Edmeades. He recalled that his brother openly opposed the decision and that one of his father's close friends spent approximately 45 minutes discussing the matter with him during his final days.
"At that stage, you know, for him, the decision was made," Edmeades said.
The experience has left Edmeades questioning whether Canada's assisted-dying program has adequate safeguards.
He acknowledged that there may be circumstances in which medically assisted dying is appropriate but argued that Canada's implementation has gone too far.
"What I see happening in Canada is way past appropriate," he said.
Edmeades also raised concerns about the government's role in overseeing the system, arguing that decisions about eligibility should be insulated from political influence and potential financial incentives.
"If I had to press a button and decide whether the MAiD program existed or didn't exist, I would say this," Edmeades said. "It should only ever exist if, and I mean if the process for approving people, it would be completely independent of government, and there could be no benefit to those people in making that preference in making that decision. Because otherwise there's a slippery slope, and we see that slippery slope."
According to the Government of Canada, individuals seeking medical assistance in dying (MAiD) must be at least 18 years old, capable of making their own medical decisions, and eligible for publicly funded healthcare.
They must also voluntarily request the procedure without outside pressure and provide informed consent. To qualify, applicants must have a serious, incurable illness, disease or disability, be experiencing an advanced and irreversible decline in their abilities and face persistent physical or psychological suffering they consider intolerable and that cannot be relieved in a way they find acceptable.
The government also announced legislation Oct. 27, 2026, that would allow advance requests while preventing the planned expansion of MAiD eligibility to people whose sole underlying medical condition is mental illness.
According to the BBC, Canada’s MAiD law, which legalized euthanasia in 2016, is responsible for one in every 20 deaths in Canada.
A report from the Canadian Medical Association Journal covered by EWTN News claimed that implementing assisted suicide will "save" the Canadian healthcare system between $34.7 and $136.8 million per year. The study noted that patients and physicians should not consider costs when making such grave decisions.
In a statement to Fox News Digital, Ian McLeod, senior advisor for media relations and Conseiller principal for the Department of Justice Canada, said, "Canadian law is extremely clear: Medical assistance in dying (MAID) requires a voluntary request, freedom from external pressure and the person’s informed consent, among other stringent eligibility criteria and safeguards. Knowingly failing to comply with these eligibility criteria and safeguards is a criminal offense.
"In the current MAiD structure found in Canada’s Criminal Code, the mental illness exclusion is meant to exclude eligibility for MAiD on the basis of a mental illness, including suicidal ideation. The proposed amendment to the mental illness exclusion in Bill C-41, the proposed Medical Assistance in Dying Safeguards Act, which was introduced on October 27, 2026, is meant to reinforce this.
"This is why the bill reinforces that, in situations where a person has a mental illness and an eligible medical condition (e.g. physical or neurodegenerative illness), eligibility must be determined on the basis of the qualifying medical condition. A mental illness may contribute to a person’s suffering, but it cannot be the basis for determining that the MAiD eligibility criteria are met. Importantly, having a mental illness does not, in itself, make a person ineligible for MAiD."
Suzanne prepares her space for a guest who has come to end their life utilizing Vermont Act 39. Suzanne, runs a retreat space for out of state patients and their families who come to end their life. Vermont's Act 39, allows for medical assistance in ending one's life when diagnosed with a terminal condition. The retreat looks out on a small range of mountains near Montpelier, Vermont on January 18, 2025.
McLeod said patients whose natural deaths are not reasonably foreseeable must undergo eligibility assessments by two independent doctors or nurse practitioners with at least 90 full days between the start of the first assessment and the assisted death.
That waiting period, according to McLeod, can be shortened if both assessments are complete, both practitioners agree the patient is at imminent risk of losing the ability to consent and the practitioner providing MAiD determines that a shorter period is appropriate.
McLeod emphasized that federal requirements establish minimum safeguards, while provinces and territories oversee how MAiD is administered and may impose additional protections. He said questions about the program's oversight and delivery should be directed to provincial or territorial authorities.
Rachel del Guidice
https://www.foxnews.com/media/son-sounds-alarm-after-fathers-medically-assisted-death-canada-way-past-appropriate
Eric Edmeades, founder of Speaker Nation, a training platform for speakers that teaches presentation skills and more, told Fox News Digital this week that his father Baz, who was in his late 70s and struggling with a combination of medical problems, began discussing Canada's Medical Assistance in Dying (MAiD) program after his health deteriorated in late 2023.
But what Edmeades expected to be a months-long process suddenly accelerated, leaving the family with little time to prepare.
Edmeades said the family started taking the issue seriously in January, but at that stage, projections were that it would take at least six months. He and his wife traveled to Vancouver at the beginning of 2024 to visit his father. At that stage, it was still a speculative thing that was months away.
"And then, all of a sudden, it was like, ‘No, it's next week,’" Edmeades recalled.
His father died via MAiD Feb. 27, 2024.
He had been experiencing a sharp decline in his physical health and independence, particularly during the COVID-era lockdowns, according to his son.
"He had been incredibly healthy most of his life," Edmeades said, describing a combination of symptoms that included epilepsy and neurological pain.
Edmeades also questioned whether interactions between his father's medications could have contributed to his deteriorating condition.
"When the lockdowns came along, and he could no longer go out and walk all the time, it really had a marked decrease in his physical ability and his sense of freedom and all that kind of stuff," he said.
"And then there just came this point where life started sounding pointless to him."
Edmeades said his father had previously spoken about suicide, making his initial interest in medically assisted dying less surprising to the family.
"Given that it wasn't the first time that he talked about suicide in his life, it wasn't particularly shocking, but he also wasn't talking about it in really alarmist terms. So, I wasn't overly worried about it," he said.
Edmeades and his wife had already planned a trip to Vancouver and were able to spend time with his father before his death.
"And one of the things I'm incredibly grateful for is that I had incidentally booked a trip out to Vancouver, and my wife and I got to spend time with him," Edmeades recalled.
He thought he and his wife would have another opportunity to visit.
Edmeades said he was not in contact with his father's medical providers at the time and did not fully understand what had happened until afterward.
"It happened so quickly that I only really started to piece together what happened when it was done," he said.
Other family members and friends had also expressed concerns about his father's decision, according to Edmeades. He recalled that his brother openly opposed the decision and that one of his father's close friends spent approximately 45 minutes discussing the matter with him during his final days.
"At that stage, you know, for him, the decision was made," Edmeades said.
The experience has left Edmeades questioning whether Canada's assisted-dying program has adequate safeguards.
He acknowledged that there may be circumstances in which medically assisted dying is appropriate but argued that Canada's implementation has gone too far.
"What I see happening in Canada is way past appropriate," he said.
Edmeades also raised concerns about the government's role in overseeing the system, arguing that decisions about eligibility should be insulated from political influence and potential financial incentives.
"If I had to press a button and decide whether the MAiD program existed or didn't exist, I would say this," Edmeades said. "It should only ever exist if, and I mean if the process for approving people, it would be completely independent of government, and there could be no benefit to those people in making that preference in making that decision. Because otherwise there's a slippery slope, and we see that slippery slope."
According to the Government of Canada, individuals seeking medical assistance in dying (MAiD) must be at least 18 years old, capable of making their own medical decisions, and eligible for publicly funded healthcare.
They must also voluntarily request the procedure without outside pressure and provide informed consent. To qualify, applicants must have a serious, incurable illness, disease or disability, be experiencing an advanced and irreversible decline in their abilities and face persistent physical or psychological suffering they consider intolerable and that cannot be relieved in a way they find acceptable.
The government also announced legislation Oct. 27, 2026, that would allow advance requests while preventing the planned expansion of MAiD eligibility to people whose sole underlying medical condition is mental illness.
According to the BBC, Canada’s MAiD law, which legalized euthanasia in 2016, is responsible for one in every 20 deaths in Canada.
A report from the Canadian Medical Association Journal covered by EWTN News claimed that implementing assisted suicide will "save" the Canadian healthcare system between $34.7 and $136.8 million per year. The study noted that patients and physicians should not consider costs when making such grave decisions.
In a statement to Fox News Digital, Ian McLeod, senior advisor for media relations and Conseiller principal for the Department of Justice Canada, said, "Canadian law is extremely clear: Medical assistance in dying (MAID) requires a voluntary request, freedom from external pressure and the person’s informed consent, among other stringent eligibility criteria and safeguards. Knowingly failing to comply with these eligibility criteria and safeguards is a criminal offense.
"In the current MAiD structure found in Canada’s Criminal Code, the mental illness exclusion is meant to exclude eligibility for MAiD on the basis of a mental illness, including suicidal ideation. The proposed amendment to the mental illness exclusion in Bill C-41, the proposed Medical Assistance in Dying Safeguards Act, which was introduced on October 27, 2026, is meant to reinforce this.
"This is why the bill reinforces that, in situations where a person has a mental illness and an eligible medical condition (e.g. physical or neurodegenerative illness), eligibility must be determined on the basis of the qualifying medical condition. A mental illness may contribute to a person’s suffering, but it cannot be the basis for determining that the MAiD eligibility criteria are met. Importantly, having a mental illness does not, in itself, make a person ineligible for MAiD."
Suzanne prepares her space for a guest who has come to end their life utilizing Vermont Act 39. Suzanne, runs a retreat space for out of state patients and their families who come to end their life. Vermont's Act 39, allows for medical assistance in ending one's life when diagnosed with a terminal condition. The retreat looks out on a small range of mountains near Montpelier, Vermont on January 18, 2025.
McLeod said patients whose natural deaths are not reasonably foreseeable must undergo eligibility assessments by two independent doctors or nurse practitioners with at least 90 full days between the start of the first assessment and the assisted death.
That waiting period, according to McLeod, can be shortened if both assessments are complete, both practitioners agree the patient is at imminent risk of losing the ability to consent and the practitioner providing MAiD determines that a shorter period is appropriate.
McLeod emphasized that federal requirements establish minimum safeguards, while provinces and territories oversee how MAiD is administered and may impose additional protections. He said questions about the program's oversight and delivery should be directed to provincial or territorial authorities.
Rachel del Guidice
https://www.foxnews.com/media/son-sounds-alarm-after-fathers-medically-assisted-death-canada-way-past-appropriate
Friday, November 6, 2026
Familial encephalopathy with neuroserpin inclusion bodies.
The disease didn’t have a name in our house. It had descriptions: the way her hands shook or she lost her words midsentence. The way she could be fully present at breakfast then somewhere unreachable by dinner.
And it had a history. My grandmother had died at 29 of what we believed was something similar, my mother had been symptomatic before I was old enough to form the question, my older sister would be told at 26 that she had it, too. What the disease had in our house was a pronoun. “It.” As in, “it got worse over the winter.” As in, “your sister might get it.” As in, “we don’t know much about it.”
There is a specific exhaustion that comes from caring for people with unnamed conditions across many years. You ask the questions when they feel fresh. You push when pushing feels possible. And then the decades accumulate and the people you were asking on behalf of are gone, and you are left with your own life to build from whatever remains, and the unanswered questions stop feeling like questions and start feeling like the way of things.
I’ve written a memoir about all of this called “Naming It.” After finishing the memoir, I sat down with the oldest document I had, my grandmother’s death certificate, which my aunt mailed me 20 years ago. I looked at it many times without understanding it, because I had not yet learned how to read it. Going through it to check a fact I stopped on cause of death: acute coronary thrombosis. A catch all. It was not an answer. It was a placeholder. It still is. In 1954, though, differential diagnosis capabilities were limited and no one looked further.
Using Claude I typed in everything I knew about what came after my grandmother’s death and my family’s history, along with the research from the ’80s and ’90s. Within seconds it answered what decades of shrugs had not. The research had worked, comparisons were made, and “it” had a name: FENIB, an ultra-rare genetic neurodegenerative disorder with progressive dementia and seizures, found in less than 1 in 1 million people. It had been named and studied for years. My family was in the literature. We had seen doctors for years. Still, no one told us.
Learning the name did not only answer a question. It reorganized everything behind it, the way a random set of details rearranges the moment you learn the one thing connecting them. I spent my life managing what the disease did. Now I understood what it was.
My grandmother handed my mother an inheritance that nobody named. My mother did the same. I can hand my children an inheritance with a name.
So I told them. Not in front of a fireplace the way I had pictured it growing up, when I was telling children who did not yet exist how I survived. This time it was at our favorite restaurant on an ordinary Wednesday. I told them everything I discovered over the previous 72 hours. The death certificate, the research, the name: FENIB.
For decades the disease in our family had only a pronoun. My children are the first generation to grow up with its name.
Miranda Pappas is a research methodologist with more than two decades of experience evaluating clinical and scientific evidence. She holds a master’s degree in counseling psychology and is the author of the forthcoming memoir “Naming It.”
https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/
Roussel BD, Lomas DA, Crowther DC. Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis). Epileptic Disord. 2016 Sep 1;18(S2):103-110. doi: 10.1684/epd.2016.0847. PMID: 27618835.
Abstract
Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is a conformational proteinopathy characterised by neuronal inclusion bodies composed of the serine protease inhibitor (SERPIN), neuroserpin. Presenting clinically as a familial dementia-epilepsy syndrome, the molecular mechanism of the pathogenic abnormalities in neuroserpin has been characterised at atomic resolution. There is a remarkable genotype-phenotype correlation between the degree of molecular destabilisation of the several variants of the neuroserpin protein, their propensity to self-associate and the age of onset of the dementia-epilepsy complex. As with other serpinopathies there appears to be a mix of cell-autonomous toxicity, due to neuronal accumulation of neuroserpin, and non-cell autonomous toxicity, caused by loss of protease inhibition, in this case the dysregulated protease is likely to be tissue plasminogen activator (tPA). FENIB should be considered in cases of progressive myoclonic epilepsy and dementia particularly where there is family history of neuropsychiatric disease.
Yang X, Fang Z, Yan L, He X, Luo H, Han Z, Gui J, Cheng M, Jiang L. Role of SERPINI1 pathogenic variants in familial encephalopathy with neuroserpin inclusion bodies: A case report and literature review. Seizure. 2022 Dec;103:137-147. doi: 10.1016/j.seizure.2022.11.008. Epub 2022 Nov 13. PMID: 36417830.
Abstract
Background: Familial encephalopathy with neuroserpin inclusion bodies (FENIB), a rare neurogenetic disease, is characterized by progressive cognitive decline and myoclonus and caused by pathogenic variants of the SERPINI1 gene that lead to the formation of neuroserpin inclusion bodies.
Methods: We described the case of an Asian patient with FENIB associated with a pathogenic variant of SERPINI1 and summarized and analyzed the clinical characteristics of the case. In addition, we conducted a literature review of previously reported patients with this disease.
Results: The patient, a 16-year-old Chinese girl, presented with progressive cognitive decline and myoclonus that had started at the age of 11 years. The girl was found to carry a de novo heterozygous c.1175G>A (p.G392E) variant of the SERPINI1 gene, which is a pathogenic variant according to the guidelines of the American College of Medical Genetics and Genomics. She had responded poorly to antiseizure medications (ASMs). At the last follow-up, her myoclonus was still out of control, and her self-care ability was poor. Our literature review revealed that 13 similar cases (including 9 cases in male patients) have been reported so far, in which six pathogenetic variations in SERPINI1, including G392E, were responsible for FENIB. All the patients presented with myoclonus, and 12 patients had experienced at least one other type of seizure. Further, as observed in our case, 9 out of 12 patients did not respond to ASMs. Progressive cognitive decline was observed in all the patients, and 10 out of 13 patients had dyskinesia. The median age of disease onset was 21 years, and the median age at the time of death was 33 years. Further, 9 out of 13 patients showed signs of cerebral and/or cerebellar atrophy. Finally, neuroserpin inclusion bodies were identified in six patients who underwent brain biopsy or autopsy.
Conclusions: Pathogenic variants of SERPINI1 should be suspected in children with progressive cognitive decline and myoclonus, especially in those with progressive myoclonus epilepsy. Further, gene detection and brain biopsy are important means for the diagnosis of FEN.
Davis RL, Holohan PD, Shrimpton AE, Tatum AH, Daucher J, Collins GH, Todd R, Bradshaw C, Kent P, Feiglin D, Rosenbaum A, Yerby MS, Shaw CM, Lacbawan F, Lawrence DA. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol. 1999 Dec;155(6):1901-13. doi: 10.1016/S0002-9440(10)65510-1. PMID: 10595921; PMCID: PMC3277299.
Abstract
We report on a new familial neurodegenerative disease with associated dementia that has presented clinically in the fifth decade, in both genders, and in each of several generations of a large family from New York State-a pattern of inheritance consistent with an autosomal dominant mode of transmission. A key pathological finding is the presence of neuronal inclusion bodies distributed throughout the gray matter of the cerebral cortex and in certain subcortical nuclei. These inclusions are distinct from any described previously and henceforth are identified as Collins bodies. The Collins bodies can be isolated by simple biochemical procedures and have a surprisingly simple composition; neuroserpin (a serine protease inhibitor) is their predominant component. An affinity-purified antibody against neuroserpin specifically labels the Collins bodies, confirming their chemical composition. Therefore, we propose a new disease entity-familial encephalopathy with neuroserpin inclusion bodies (FENIB). The conclusion that FENIB is a previously unrecognized neurodegenerative disease is supported by finding Collins bodies in a small kindred from Oregon with familial dementia who are unrelated to the New York family. The autosomal dominant inheritance strongly suggests that FENIB is caused by mutations in the neuroserpin gene, resulting in intracellular accumulation of the mutant protein.
And it had a history. My grandmother had died at 29 of what we believed was something similar, my mother had been symptomatic before I was old enough to form the question, my older sister would be told at 26 that she had it, too. What the disease had in our house was a pronoun. “It.” As in, “it got worse over the winter.” As in, “your sister might get it.” As in, “we don’t know much about it.”
The author, far right, with her sister and mother in 1990.
That last sentence was repeated so many times, by so many doctors, that it stopped feeling like an update and started feeling like a fact about the world. Some things were known. This wasn’t one of them. We filed it alongside questions that were genuinely unanswerable, not worth revisiting.
We were wrong about that. I just didn’t know it yet.
I grew up as the primary caregiver for my mother from roughly age 8‚ managing the household, bridging the gap between what was happening inside our walls and what we presented to the world outside them. By the time I was old enough to understand what I was doing, I had already been doing it for years, not because anyone assigned it to me explicitly but because someone had to and I was there and I was capable, and it turned out that capability was its own kind of assignment.
The disease organized my childhood the way weather organizes a farming life. You don’t fight it, you work around it, you learn its seasons. And somewhere in the years of working around it, you stop asking what it is and start managing what it does.
Three generations of women in my family — my grandmother, my mother, my sister — carried the same condition through the same blood before any of us had a clinical word for it. Fifty years of documented family history. Fifty years of doctors who shrugged with genuine sympathy and said, rare. Poorly understood. Difficult to characterize.
I believed them for a long time.
Here is something worth knowing about the category called rare disease. Rare does not mean unknown. It usually means underresearched, underfunded, and underconnected to the people living inside it. There are approximately 7,000 to 10,000 identified rare diseases, depending on what definition you use. Many of them have names, and many have researchers who have dedicated careers to a single mutation, a single protein, a single entry point into the vast underlit territory of conditions that affect small numbers of people and therefore attract small amounts of attention and money.
The work on these diseases gets done‚ slowly, in small labs, by scientists who chose a difficult corner of medicine because something drew them there. The work gets published. The knowledge accumulates.
And then, in too many cases, it stays there. There is no architecture reliably connecting what medicine knows about a rare condition to the families living inside it. Research participants from earlier decades have no right to follow-up notification. Families whose cases contributed to literature that eventually named their disease may never know the paper was written.
The loop, opened when the family first came to medical attention, can stay open indefinitely on their end. On the other end, in a database they don’t know to search, the loop may have closed years ago. This is not malice, it’s infrastructure, but the cost is real regardless.
The cost is my mother going through nearly 40 years of illness without being told that someone had looked at what she had and given it a name. The cost is my sister and her 15 years of deterioration and her death at 41, in a world where a researcher somewhere had been asking the same questions we asked in our living room, except the researcher was getting answers and we were not getting calls.
I am a research methodologist. For 23 years I have worked at an academic medical center building systematic reviews‚ assembling bodies of medical literature to answer clinical questions, following citation chains, evaluating sources, asking the next question without assuming the answer. I had the skills and the access and I had stopped looking, and that is the sentence I keep coming back to. I had stopped asking the question that mattered most to me personally‚ not because I forgot, not because I stopped caring, but because somewhere in the decades of shrugged answers, I had accepted the not-knowing as the settled state. The doctors had said rare, poorly understood, difficult to characterize for so long that I had internalized their uncertainty as my own. A research methodologist’s skill set and a grieving daughter’s resignation, and the resignation had won.
That last sentence was repeated so many times, by so many doctors, that it stopped feeling like an update and started feeling like a fact about the world. Some things were known. This wasn’t one of them. We filed it alongside questions that were genuinely unanswerable, not worth revisiting.
We were wrong about that. I just didn’t know it yet.
I grew up as the primary caregiver for my mother from roughly age 8‚ managing the household, bridging the gap between what was happening inside our walls and what we presented to the world outside them. By the time I was old enough to understand what I was doing, I had already been doing it for years, not because anyone assigned it to me explicitly but because someone had to and I was there and I was capable, and it turned out that capability was its own kind of assignment.
The disease organized my childhood the way weather organizes a farming life. You don’t fight it, you work around it, you learn its seasons. And somewhere in the years of working around it, you stop asking what it is and start managing what it does.
Three generations of women in my family — my grandmother, my mother, my sister — carried the same condition through the same blood before any of us had a clinical word for it. Fifty years of documented family history. Fifty years of doctors who shrugged with genuine sympathy and said, rare. Poorly understood. Difficult to characterize.
I believed them for a long time.
Here is something worth knowing about the category called rare disease. Rare does not mean unknown. It usually means underresearched, underfunded, and underconnected to the people living inside it. There are approximately 7,000 to 10,000 identified rare diseases, depending on what definition you use. Many of them have names, and many have researchers who have dedicated careers to a single mutation, a single protein, a single entry point into the vast underlit territory of conditions that affect small numbers of people and therefore attract small amounts of attention and money.
The work on these diseases gets done‚ slowly, in small labs, by scientists who chose a difficult corner of medicine because something drew them there. The work gets published. The knowledge accumulates.
And then, in too many cases, it stays there. There is no architecture reliably connecting what medicine knows about a rare condition to the families living inside it. Research participants from earlier decades have no right to follow-up notification. Families whose cases contributed to literature that eventually named their disease may never know the paper was written.
The loop, opened when the family first came to medical attention, can stay open indefinitely on their end. On the other end, in a database they don’t know to search, the loop may have closed years ago. This is not malice, it’s infrastructure, but the cost is real regardless.
The cost is my mother going through nearly 40 years of illness without being told that someone had looked at what she had and given it a name. The cost is my sister and her 15 years of deterioration and her death at 41, in a world where a researcher somewhere had been asking the same questions we asked in our living room, except the researcher was getting answers and we were not getting calls.
I am a research methodologist. For 23 years I have worked at an academic medical center building systematic reviews‚ assembling bodies of medical literature to answer clinical questions, following citation chains, evaluating sources, asking the next question without assuming the answer. I had the skills and the access and I had stopped looking, and that is the sentence I keep coming back to. I had stopped asking the question that mattered most to me personally‚ not because I forgot, not because I stopped caring, but because somewhere in the decades of shrugged answers, I had accepted the not-knowing as the settled state. The doctors had said rare, poorly understood, difficult to characterize for so long that I had internalized their uncertainty as my own. A research methodologist’s skill set and a grieving daughter’s resignation, and the resignation had won.
The author, her baby son, and her mother.
There is a specific exhaustion that comes from caring for people with unnamed conditions across many years. You ask the questions when they feel fresh. You push when pushing feels possible. And then the decades accumulate and the people you were asking on behalf of are gone, and you are left with your own life to build from whatever remains, and the unanswered questions stop feeling like questions and start feeling like the way of things.
I’ve written a memoir about all of this called “Naming It.” After finishing the memoir, I sat down with the oldest document I had, my grandmother’s death certificate, which my aunt mailed me 20 years ago. I looked at it many times without understanding it, because I had not yet learned how to read it. Going through it to check a fact I stopped on cause of death: acute coronary thrombosis. A catch all. It was not an answer. It was a placeholder. It still is. In 1954, though, differential diagnosis capabilities were limited and no one looked further.
Using Claude I typed in everything I knew about what came after my grandmother’s death and my family’s history, along with the research from the ’80s and ’90s. Within seconds it answered what decades of shrugs had not. The research had worked, comparisons were made, and “it” had a name: FENIB, an ultra-rare genetic neurodegenerative disorder with progressive dementia and seizures, found in less than 1 in 1 million people. It had been named and studied for years. My family was in the literature. We had seen doctors for years. Still, no one told us.
Learning the name did not only answer a question. It reorganized everything behind it, the way a random set of details rearranges the moment you learn the one thing connecting them. I spent my life managing what the disease did. Now I understood what it was.
My grandmother handed my mother an inheritance that nobody named. My mother did the same. I can hand my children an inheritance with a name.
So I told them. Not in front of a fireplace the way I had pictured it growing up, when I was telling children who did not yet exist how I survived. This time it was at our favorite restaurant on an ordinary Wednesday. I told them everything I discovered over the previous 72 hours. The death certificate, the research, the name: FENIB.
For decades the disease in our family had only a pronoun. My children are the first generation to grow up with its name.
Miranda Pappas is a research methodologist with more than two decades of experience evaluating clinical and scientific evidence. She holds a master’s degree in counseling psychology and is the author of the forthcoming memoir “Naming It.”
https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/
Roussel BD, Lomas DA, Crowther DC. Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis). Epileptic Disord. 2016 Sep 1;18(S2):103-110. doi: 10.1684/epd.2016.0847. PMID: 27618835.
Abstract
Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is a conformational proteinopathy characterised by neuronal inclusion bodies composed of the serine protease inhibitor (SERPIN), neuroserpin. Presenting clinically as a familial dementia-epilepsy syndrome, the molecular mechanism of the pathogenic abnormalities in neuroserpin has been characterised at atomic resolution. There is a remarkable genotype-phenotype correlation between the degree of molecular destabilisation of the several variants of the neuroserpin protein, their propensity to self-associate and the age of onset of the dementia-epilepsy complex. As with other serpinopathies there appears to be a mix of cell-autonomous toxicity, due to neuronal accumulation of neuroserpin, and non-cell autonomous toxicity, caused by loss of protease inhibition, in this case the dysregulated protease is likely to be tissue plasminogen activator (tPA). FENIB should be considered in cases of progressive myoclonic epilepsy and dementia particularly where there is family history of neuropsychiatric disease.
Yang X, Fang Z, Yan L, He X, Luo H, Han Z, Gui J, Cheng M, Jiang L. Role of SERPINI1 pathogenic variants in familial encephalopathy with neuroserpin inclusion bodies: A case report and literature review. Seizure. 2022 Dec;103:137-147. doi: 10.1016/j.seizure.2022.11.008. Epub 2022 Nov 13. PMID: 36417830.
Abstract
Background: Familial encephalopathy with neuroserpin inclusion bodies (FENIB), a rare neurogenetic disease, is characterized by progressive cognitive decline and myoclonus and caused by pathogenic variants of the SERPINI1 gene that lead to the formation of neuroserpin inclusion bodies.
Methods: We described the case of an Asian patient with FENIB associated with a pathogenic variant of SERPINI1 and summarized and analyzed the clinical characteristics of the case. In addition, we conducted a literature review of previously reported patients with this disease.
Results: The patient, a 16-year-old Chinese girl, presented with progressive cognitive decline and myoclonus that had started at the age of 11 years. The girl was found to carry a de novo heterozygous c.1175G>A (p.G392E) variant of the SERPINI1 gene, which is a pathogenic variant according to the guidelines of the American College of Medical Genetics and Genomics. She had responded poorly to antiseizure medications (ASMs). At the last follow-up, her myoclonus was still out of control, and her self-care ability was poor. Our literature review revealed that 13 similar cases (including 9 cases in male patients) have been reported so far, in which six pathogenetic variations in SERPINI1, including G392E, were responsible for FENIB. All the patients presented with myoclonus, and 12 patients had experienced at least one other type of seizure. Further, as observed in our case, 9 out of 12 patients did not respond to ASMs. Progressive cognitive decline was observed in all the patients, and 10 out of 13 patients had dyskinesia. The median age of disease onset was 21 years, and the median age at the time of death was 33 years. Further, 9 out of 13 patients showed signs of cerebral and/or cerebellar atrophy. Finally, neuroserpin inclusion bodies were identified in six patients who underwent brain biopsy or autopsy.
Conclusions: Pathogenic variants of SERPINI1 should be suspected in children with progressive cognitive decline and myoclonus, especially in those with progressive myoclonus epilepsy. Further, gene detection and brain biopsy are important means for the diagnosis of FEN.
Davis RL, Holohan PD, Shrimpton AE, Tatum AH, Daucher J, Collins GH, Todd R, Bradshaw C, Kent P, Feiglin D, Rosenbaum A, Yerby MS, Shaw CM, Lacbawan F, Lawrence DA. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol. 1999 Dec;155(6):1901-13. doi: 10.1016/S0002-9440(10)65510-1. PMID: 10595921; PMCID: PMC3277299.
Abstract
We report on a new familial neurodegenerative disease with associated dementia that has presented clinically in the fifth decade, in both genders, and in each of several generations of a large family from New York State-a pattern of inheritance consistent with an autosomal dominant mode of transmission. A key pathological finding is the presence of neuronal inclusion bodies distributed throughout the gray matter of the cerebral cortex and in certain subcortical nuclei. These inclusions are distinct from any described previously and henceforth are identified as Collins bodies. The Collins bodies can be isolated by simple biochemical procedures and have a surprisingly simple composition; neuroserpin (a serine protease inhibitor) is their predominant component. An affinity-purified antibody against neuroserpin specifically labels the Collins bodies, confirming their chemical composition. Therefore, we propose a new disease entity-familial encephalopathy with neuroserpin inclusion bodies (FENIB). The conclusion that FENIB is a previously unrecognized neurodegenerative disease is supported by finding Collins bodies in a small kindred from Oregon with familial dementia who are unrelated to the New York family. The autosomal dominant inheritance strongly suggests that FENIB is caused by mutations in the neuroserpin gene, resulting in intracellular accumulation of the mutant protein.
Thursday, November 5, 2026
Rhabdomyolysis
Rachel Apa collapsed near mile 24 of the New York City Marathon, a few hours after telling her dad she felt “amazing”
The former Bucknell hockey player died later that night from rhabdomyolysis, or muscle breakdown
An expert says gradual training and recognizing warning signs can help reduce exertion-related risks
A 24-year-old woman in “perfect health” collapsed while running her first marathon, and died later that night. Her cause of death was a life-threatening condition often associated with over-exertion: rhabdomyolysis.
Rachel Apa, an athlete and former hockey player for Bucknell University, was running her first marathon, the New York City Marathon, on Nov. 1. Early in the race, around 11:30 a.m., near the 9-mile mark, she texted her father, Steve Apa. Shortly afterward, she texted him “I feel amazing,” and “I’ve never felt this good,” he told NBC.
But around 1:30, her texts changed, with Rachel texting her father “ow.” Soon, her replies stopped, and she reportedly collapsed near mile 24, two miles shy of the 26.2-mile finish line. She later died at the hospital.
“It’s unfathomable,” her dad told The New York Times. “Perfect health, perfect shape, 24 years old.”
It was determined that Apa died of rhabdomyolysis (often shortened to rhabdo). In simplest terms, it means “muscle breakdown,” Dr. Sohaib Imtiaz, Chief Medical Officer at People Inc., says.
“It can happen when extreme effort combines with other risk factors: heat, dehydration, painkillers like ibuprofen, a recent virus, or a hidden genetic condition, such as sickle cell trait or certain inherited muscle disorders,” Imtiaz, who did not treat Apa, explains.
There is no information about what specifically led to Apa’s rhabdo.
In the fatal condition, Imtiaz says, it’s not the damaged muscles that cause the problem, but what the muscle breakdown does to the body. It can cause “a dangerous spike in potassium that can stop the heart, as well as kidney failure, a sharp drop in blood pressure, or problems with blood clotting,” he says, adding that heat stroke can occur at the same time.
“Deadly exertional rhabdomyolysis in a young, fit runner is rare,” Imtiaz says, but it can happen — especially over hours of exertion.
During “hard running, muscles take repeated strain,” he says. “Over time, the muscle cells run out of energy and die. As they break apart, they release their contents, including potassium and a protein called myoglobin, into the blood.”
While rhabdo is often associated with pain, it’s not uncommon for someone to feel great before it hits, Imtiaz says.
“Many people never have the textbook combination of muscle pain, weakness and dark urine, so serious damage can build quietly. Rising potassium causes no symptoms until it suddenly disrupts the heart’s rhythm,” he explains. Also, “rhabdo and early heat illness can cause confusion, which may change how someone judges how they feel before anyone around them notices.”
And, he adds, rhabdo may come on suddenly. “A heart rhythm problem caused by high potassium gives little warning, so someone can feel fine and then collapse.”
He urges people to be on alert for warning signs that indicate the pain is more than just normal soreness, like “muscle pain that’s worse or lasts longer than expected, especially with swelling, firmness, weakness or trouble moving,” as well as dark urine — or barely urinating at all — along with nausea, vomiting, fever, unusual tiredness, confusion or agitation.
“Most cases happen when people push past what their body is used to.” So build up your endurance gradually, he says. And on hot or humid days, take it easy, as “heat is one of the biggest risk factors” in developing the condition.
And while hydration is important, Imtiaz warns not to overdo plain water that can dilute sodium to dangerous low levels in the blood.
Overall, he says, “Pay attention to the warning signs. It’s crucial to get medical help right away. Don’t wait it out.”
Cara Lynn Shultz
https://people.com/marathon-runner-dies-rhabdomyolysis-medical-expert-exclusive-12228322
The former Bucknell hockey player died later that night from rhabdomyolysis, or muscle breakdown
An expert says gradual training and recognizing warning signs can help reduce exertion-related risks
A 24-year-old woman in “perfect health” collapsed while running her first marathon, and died later that night. Her cause of death was a life-threatening condition often associated with over-exertion: rhabdomyolysis.
Rachel Apa, an athlete and former hockey player for Bucknell University, was running her first marathon, the New York City Marathon, on Nov. 1. Early in the race, around 11:30 a.m., near the 9-mile mark, she texted her father, Steve Apa. Shortly afterward, she texted him “I feel amazing,” and “I’ve never felt this good,” he told NBC.
But around 1:30, her texts changed, with Rachel texting her father “ow.” Soon, her replies stopped, and she reportedly collapsed near mile 24, two miles shy of the 26.2-mile finish line. She later died at the hospital.
“It’s unfathomable,” her dad told The New York Times. “Perfect health, perfect shape, 24 years old.”
It was determined that Apa died of rhabdomyolysis (often shortened to rhabdo). In simplest terms, it means “muscle breakdown,” Dr. Sohaib Imtiaz, Chief Medical Officer at People Inc., says.
“It can happen when extreme effort combines with other risk factors: heat, dehydration, painkillers like ibuprofen, a recent virus, or a hidden genetic condition, such as sickle cell trait or certain inherited muscle disorders,” Imtiaz, who did not treat Apa, explains.
There is no information about what specifically led to Apa’s rhabdo.
In the fatal condition, Imtiaz says, it’s not the damaged muscles that cause the problem, but what the muscle breakdown does to the body. It can cause “a dangerous spike in potassium that can stop the heart, as well as kidney failure, a sharp drop in blood pressure, or problems with blood clotting,” he says, adding that heat stroke can occur at the same time.
“Deadly exertional rhabdomyolysis in a young, fit runner is rare,” Imtiaz says, but it can happen — especially over hours of exertion.
During “hard running, muscles take repeated strain,” he says. “Over time, the muscle cells run out of energy and die. As they break apart, they release their contents, including potassium and a protein called myoglobin, into the blood.”
While rhabdo is often associated with pain, it’s not uncommon for someone to feel great before it hits, Imtiaz says.
“Many people never have the textbook combination of muscle pain, weakness and dark urine, so serious damage can build quietly. Rising potassium causes no symptoms until it suddenly disrupts the heart’s rhythm,” he explains. Also, “rhabdo and early heat illness can cause confusion, which may change how someone judges how they feel before anyone around them notices.”
And, he adds, rhabdo may come on suddenly. “A heart rhythm problem caused by high potassium gives little warning, so someone can feel fine and then collapse.”
He urges people to be on alert for warning signs that indicate the pain is more than just normal soreness, like “muscle pain that’s worse or lasts longer than expected, especially with swelling, firmness, weakness or trouble moving,” as well as dark urine — or barely urinating at all — along with nausea, vomiting, fever, unusual tiredness, confusion or agitation.
“Most cases happen when people push past what their body is used to.” So build up your endurance gradually, he says. And on hot or humid days, take it easy, as “heat is one of the biggest risk factors” in developing the condition.
And while hydration is important, Imtiaz warns not to overdo plain water that can dilute sodium to dangerous low levels in the blood.
Overall, he says, “Pay attention to the warning signs. It’s crucial to get medical help right away. Don’t wait it out.”
Cara Lynn Shultz
https://people.com/marathon-runner-dies-rhabdomyolysis-medical-expert-exclusive-12228322
Subscribe to:
Posts (Atom)

